• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Application of 5-Bromo-2-methylnicotinic Acid (CAS: 351003-02-6) in Chemical Biology and Pharmaceutical Research

5-Bromo-2-methylnicotinic acid (CAS: 351003-02-6) is a brominated nicotinic acid derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other small-molecule therapeutics. Recent studies have highlighted its potential in targeting specific enzymatic pathways, making it a valuable scaffold for the design of novel pharmaceutical agents.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 5-bromo-2-methylnicotinic acid as a building block for the synthesis of potent and selective kinase inhibitors. The researchers utilized this compound to develop a series of derivatives that exhibited nanomolar inhibitory activity against specific tyrosine kinases implicated in cancer progression. The study emphasized the compound's favorable physicochemical properties, which contribute to improved drug-like characteristics such as solubility and metabolic stability.

In the field of chemical biology, 5-bromo-2-methylnicotinic acid has been employed as a versatile handle for bioconjugation strategies. A recent Nature Chemical Biology publication (2024) described its use in the development of activity-based probes for studying enzyme function in live cells. The bromo substituent at the 5-position allows for efficient cross-coupling reactions, enabling the attachment of various reporter groups while maintaining the compound's biological activity.

Pharmaceutical applications of this compound have expanded significantly, with several patent applications filed in 2023-2024 describing its incorporation into drug candidates for inflammatory diseases and metabolic disorders. One notable example is its use in the development of allosteric modulators for G-protein coupled receptors (GPCRs), where the methyl group at the 2-position appears to play a crucial role in receptor binding specificity.

Recent synthetic methodology developments have also improved access to 5-bromo-2-methylnicotinic acid and its derivatives. A 2024 Organic Process Research & Development paper reported a scalable, environmentally friendly synthesis route that reduces the need for hazardous reagents while maintaining high yields. This advancement is particularly important for potential industrial-scale production of pharmaceuticals containing this structural motif.

Emerging research suggests that 5-bromo-2-methylnicotinic acid derivatives may have applications beyond traditional small-molecule therapeutics. A 2024 ACS Chemical Biology study demonstrated their potential in targeted protein degradation strategies, where they were incorporated into proteolysis-targeting chimeras (PROTACs) designed to selectively degrade disease-relevant proteins.

In conclusion, 5-bromo-2-methylnicotinic acid (351003-02-6) continues to be a valuable compound in chemical biology and pharmaceutical research, with recent studies expanding its applications in drug discovery, chemical probe development, and novel therapeutic modalities. The compound's structural features and synthetic accessibility make it likely to remain an important tool in medicinal chemistry for the foreseeable future.

• 20826-04-4(5-bromopyridine-3-carboxylic acid)
• 3222-56-8(2-methylpyridine-3-carboxylic acid)
• 98555-51-2(5-Bromopyridine-2,3-dicarboxylic acid)
• 129477-21-0(ethyl 5-bromo-2-methylpyridine-3-carboxylate)
• 886365-43-1(5-Bromo-3-methylpyridine-2-carboxylic acid)
• 92513-39-8(6-Bromo-2-methylquinoline-3-carboxylic acid)
• 610277-19-5(7-bromo-2-methylquinoline-3-carboxylic acid)
• 1190862-72-6(5-bromo-6-methylpyridine-3-carboxylic acid)
• 1060805-98-2(4-Bromo-2-methylnicotinic acid)
• 93350-01-7(5-bromo-4,6-dimethyl-pyridine-3-carboxylic acid)